Anti-Nucleocapsid Protein Immune Responses Counteract Pathogenic Effects of Rift Valley Fever Virus Infection in Mice
2011

Protective Immune Responses Against Rift Valley Fever Virus in Mice

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Jansen van Vuren Petrus, Tiemessen Caroline T., Paweska Janusz T.

Primary Institution: National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa

Hypothesis

The study evaluates the immune responses elicited by a recombinant nucleocapsid protein of Rift Valley fever virus in mice.

Conclusion

Immunization with the recombinant nucleocapsid protein led to an earlier type I interferon response and reduced viral replication in mice compared to non-immunized controls.

Supporting Evidence

  • Immunized mice showed a stronger immune response compared to non-immunized controls.
  • The study identified specific genes involved in the immune response to the virus.
  • High viral titers were associated with downregulation of immune response genes in non-immunized mice.

Takeaway

Researchers gave mice a special vaccine to help them fight off a virus, and it worked better than not having the vaccine at all.

Methodology

Mice were immunized with a recombinant nucleocapsid protein combined with an adjuvant, followed by a challenge with wild type Rift Valley fever virus.

Potential Biases

Potential bias in the selection of mouse strains and the specific immune responses measured.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Four-week old female BALB/cOlaHsd mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0025027

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication